You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for New Drug Application (NDA): 021064


✉ Email this page to a colleague

« Back to Dashboard


NDA 021064 describes DEFINITY RT, which is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. Additional details are available on the DEFINITY RT profile page.

The generic ingredient in DEFINITY RT is perflutren. One supplier is listed for this compound. Additional details are available on the perflutren profile page.
Summary for 021064
Tradename:DEFINITY RT
Applicant:Lantheus Medcl
Ingredient:perflutren
Patents:10
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 021064
Generic Entry Date for 021064*:
Constraining patent/regulatory exclusivity:
Dosage:
INJECTABLE;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 021064
Mechanism of ActionUltrasound Contrast Activity
Suppliers and Packaging for NDA: 021064
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064 NDA Lantheus Medical Imaging, Inc. 11994-011 11994-011-01 1 VIAL, GLASS in 1 CARTON (11994-011-01) / 1.5 mL in 1 VIAL, GLASS
DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064 NDA Lantheus Medical Imaging, Inc. 11994-011 11994-011-01 1 VIAL, GLASS in 1 CARTON (11994-011-01) / 1.5 mL in 1 VIAL, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVENOUSStrength13.04MG/2ML (6.52MG/ML)
Approval Date:Jul 31, 2001TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Dec 28, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
Patent:⤷  Sign UpPatent Expiration:Mar 16, 2037Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
Patent:⤷  Sign UpPatent Expiration:May 4, 2037Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Expired US Patents for NDA 021064

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ⤷  Sign Up ⤷  Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ⤷  Sign Up ⤷  Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ⤷  Sign Up ⤷  Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ⤷  Sign Up ⤷  Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ⤷  Sign Up ⤷  Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ⤷  Sign Up ⤷  Sign Up
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.